Treating carbapenem-resistant Acinetobacter baumannii infections
- PMID: 37182533
- DOI: 10.1016/S1473-3099(23)00203-7
Treating carbapenem-resistant Acinetobacter baumannii infections
Conflict of interest statement
MG and PV have received personal payments for speaking at educational events supported by Pfizer, MSD, Shionogi, Menarini, Gilead, Bio Merieux, and Termo Fisher in the past 36 months.
Comment on
-
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).Lancet Infect Dis. 2023 Sep;23(9):1072-1084. doi: 10.1016/S1473-3099(23)00184-6. Epub 2023 May 11. Lancet Infect Dis. 2023. PMID: 37182534 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources